Prediction of human intestinal absorption of drug compounds from molecular structure

Journal of Chemical Information and Computer Sciences

Volumn 38, Issue 4, 1998, Pages 726-735

  Wessel, Matthew D ^a   Jurs, Peter C ^a   Tolan, John W ^b   Muskal, Steven M ^b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b AFFYMAX RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; ARTIFICIAL NEURAL NETWORK; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; HUMAN; INTESTINE ABSORPTION; PHARMACOKINETICS; STATISTICAL MODEL; STRUCTURE ACTIVITY RELATION;

HUMANS; INTESTINAL ABSORPTION; LINEAR MODELS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NEURAL NETWORKS (COMPUTER); PHARMACOKINETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032112107     PISSN: 00952338     EISSN: None     Source Type: Journal    
DOI: 10.1021/ci980029a     Document Type: Article

References (176)

1. Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gordon, E. M. Application of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries. J. Med. Chem. 1994, 37, 1233-1251.
2. Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gallop, M. A. Applications of Combinatorial Technologies to Drug Discovery. 2. Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions. J. Med. Chem. 1994, 37, 1385-1401.
3. Stewart, B. H.; Chan, O. H.; Lu, R. H.; Reyner, E. L.; Schmid, H. L.; Hamilton, H. W.; Steinbaugh, B. A.; Taylor, M. D. Comparison of Intestinal Permeabilities Determined in Multiple In Vitro and In Situ Models: Relationship to Absorption in Humans Pharm. Res. 1995, 13, 693-699.
4. Rubas, W.; Jezyk, N.; Grass, G. M. Comparison of the Permeability Characteristics of a Series of Peptides Using an In Vitro Cell Culture Model (Caco-2) and Those Using an In Situ Perfused Rat Ileum Model of the Intestinal Mucosa. Pharm. Res. 1993, 10, 113-118.
5. Kim, D. C.; Burton, P. S.; Borchardt, R. T. A Correlation Between the Permeability Characteristics of a Series of Peptides Using an In Vitro Cell Culture Model (Caco-2) and Those Using an In Situ Perfused Rat Ileum Model of the Intestinal Mucosa. Pharm. Res. 1993, 10, 1710-1714.
6. Hidalgo, I. J.; Raub, T. J.; Borchardt, R. T. Characterization of the Human Colon Carcinoma Cell Line (Caco-2) as a Model System for Intestinal Epithelial Permeability. Gastroenterology 1989, 96, 736-749.
7. Artursson, P. Cell Cultures as Models for Drug Absorption Across the Intestinal Mucosa. Crit. Rev. Drug Carrier Systems 1991, 8, 305-330.
8. Gan, L.-S.; Eads, C.; Niederer, T.; Bridgers, A.; Yanni, S.; Hsyu, P.-H.; Pritchard, F. J.; Thackker, D. Use of Caco-2 Cells as an In Vitro Intestinal Absorption and Metabolic Model. Drug Dev. Ind. Pharm. 1994, 20, 615-631.
9. Artursson, P.; Palm, K.; Luthman, K. Caco-2 Monolayers in Expertmental and Theoretical Predictions of Drug Transport. Adv. Drug Del. Rev. 1996, 22, 67-84.
10. Rubas, W.; Cromwell, M. E.; Shahrokh, Z.; Villagran, J.; Nguyen, T. N.; Wellton, M.; Nguyen, T. H.; Mrsny, R. J. Flux Measurements Across Caco-2 Monolayers may Predict Transport in Human Large Intestinal Tissue. J. Pharm. Sci. 1996, 85, 165-169.
11. Yee, S. In Vitro Permeability Across Caco-2 Cells (Colonic) can Predict In Vivo (Small Intestinal) Absorption in Man - Fact or Myth. Pharm. Res. 1997, 34, 1242-1250.
12. Wang, S.; Milne, G. W. A.; Klopman, G. Graph Theory and Group Contribution in the Estimation of Boiling Points. J. Chem. Inf. Comput. Sci. 1994, 34, 1242-1250.
13. Wessel, M. D.; Sutter, J. M.; Jurs, P. C. Prediction of Reduced Ion Mobility Constants of Organic Compounds from Molecular Structure. Anal. Chem. 1996, 63, 4237-4243.
14. Stanton, D. T.; Jurs, P. C. Computer-Assisted Prediction of Gas Chromatographic Retention Indices of Pyrazines. Anal. Chem. 1989, 61, 1328-1332.
15. Hasan, M. N.; Jurs, P. C. Prediction of Gas and Liquid Chromatographic Retention Indices of Polyhalogenated Biphenyls. Anal. Chem. 1990, 62, 2318-2323.
16. Anker, L. S.; Jurs, P. C. Prediction of Carbon-13 Nuclear Magnetic Resonance Chemical Shifts by Artificial Neural Networks. Anal. Chem. 1992, 64, 1157-1164.
17. Johnson, S. R.; Jurs, P. C. Prediction of Acute Mammalian Toxicity from Molecular Structure for a Diverse Set of Substituted Anilines Using Regression Regression Analysis and Computational Neural Networks. In Computer-Assisted Lead Finding and Optimization; van de Waterbeemd, H., Testa, B.; Folkers, G., Eds.; Wiley-VCH: New York, 1997; pp 29-48.
18. Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: New York, 1995; Vol. 2.
19. Dressman, J. B.; Amidon, G. L.; Fleisher, D. Absorption Potential: Estimating the Fraction Absorbed for Orally Administered Compounds. J. Pharm. Sci. 1985, 74, 588-589.
20. Hamilton, H. W.; Steinbaugh, B. A.; Stewart, B. H.; Chan, O. H.; Schmid, H. L.; Schroeder, R.; Ryan, M. J.; Keiser, J.; Taylor, M. D.; Blankley, C. J.; Kalttenbronn, J. S.; Wright, J.; Hicks, J. Evaluation of Physicochemical Parameters Important to the Oral Bioavailability of Peptide-Like Compounds: Implications for the Synthesis of Renin Inhibitors. J. Med. Chem. 1995, 38, 1446-1455.
21. Palm, K.; Luthman, K.; Ungell, A. L.; Strandlund, G.; Artursson, P. Correlation of Drug Absorption with Molecular Surface Properties. J. Pharm. Sci. 1996, 85, 32-39.
22. Abraham, M. H.; Chadha, H. S.; Mitchell, R. C. Hydrogen Bonding. 33. Factors that Influence the Distribution of Solutes Between Blood and Brain. J. Pharm. Sci. 1994, 83, 1257-1268.
23. Basak, S. C.; Gute, B. D.; Drewes, E. R. Predicting Blood-Brain Transport of Drugs: A Computational Approach. Pharm. Res. 1996, 13, 775-778.
24. Potts, R. O.; Guy, R. H. A Predictive Algorithm for Skin Permeability: The Effects of Molecular Size and Hydrogen Bond Activity. Pharm. Res. 1995, 12, 1628-1663.
25. Yoshida, F.; Topliss, J. G. Unified Model for the Corneal Permeability of Related and Diverse Compounds with Respect to Their Physicochemical Properties. J. Pharm. Sci. 1996, 85, 819-823.
26. Kaul, S.; Ritschel, W. A. Quantitative Structure- -Pharmacokinetic Relationship of a Series of Sulfonamides in the Rat. Eur. J. Drug Metab. Pharmacokinet. 1990, 15, 211-217.
27. Gobburu, J. V. S.; Shelver, W. H. Quantitative Structure-Pharmacokinetic Relationships (QSPR) of Beta Blockers Derived Using Neural Networks. J. Pharm. Sci. 1995, 84, 862-865.
28. Cupid, B. C.; Beddell, C. R.; Lindon, J. C.; Wilson, I. D.; Nicholson, J. K. Quantitative Structure-Metabolism Relationships for Substituted Benzoic Acids in the Rabbit: Prediction of Urinary Excretion of Glycine and Glucuronide Conjugates. Xenobiotica 1996, 26, 157-176.
29. Lucasius, C. B.; Kateman, G. Understanding and Using Genetic Algorithms Part 1. Concepts, Properties and Context. Chemom. Intell. Lab. Sys. 1993, 19, 1.
30. Hibbert, D. B. A Hybrid Genetic Algorithm for the Estimation of Kinetic Parameters. Chemom. Intell. Lab. Sys. 1993, 19, 319-329.
31. Xu, L.; Ball, J. W.; Dixon, S. L.; Jurs, P. C. Quantitative Structure-Activity Relationships for Toxicity of Phenols Using Regression Analysis and Computational Neural Networks. Environ. Toxicol. Chem. 1994, 13, 841-851.
32. Hammet, L. P. The Effect of Structure upon the Reactions of Organic Compounds. Benzene Derivatives. J. Am. Chem. Soc. 1937, 59, 96-103.
33. Hansch, C.; Maloney, P. P.; Fujita, T.; Muir, R. Correlation of Biological Activity of Phenoxyacetic Acids with Hammet Substituent Constants and Partitition Coefficients. Nature 1962, 194, 178-180.
34. Hansch, C. A. Quantitative Approach to Biochemical Structure - Activity Relationships. Acc. Chem. Res. 1969, 2, 232-239.
35. Hansch, C. Quantitative Structure - Activity Relationships and the Unnamed Science. Acc. Chem. Res. 1993, 2, 147-153.
36. Hypercube, Inc. 1115 NW 4th Street, Gainsville, FL 32601-4256.
37. Sadowski, J.; Gasteiger, J. From Atoms to Bonds to Three-Dimensional Atomic Coordinates: Automatic Model Builders. Chem. Rev. 1993, 93, 2567-2581.
38. Stuper, A. J.; Brugger, W. E.; Jurs, P. C. Computer-Assisted Studies of Chemical Structure and Biological Function; Wiley-Interscience: New York, 1979.
39. Jurs, P. C.; Chou, J. T.; Yuan, M. In Computer-Assisted Drug Design; Olson, E. C., Christoffersen, R. E., Eds.; The American Chemical Society: Washington, D.C., 1979; pp 103-129.
40. Latini, R.; Cerletti, C.; de Gaetano, G.; Dejana, E.; Galletti, F.; Urso, R.; Marzot, M. Comparative Bioavailability of Aspirin from Buffered, Enteric-Coated and Plain Preparations. Int. J. Clin. Pharmacol. Ther. Toxicol. 1986, 24, 313-318.
41. Gabriel, R.; Kaye, C. M.; Sankey, M. G. Preliminary Observations on the Excretion of Acebutolol and its Acetyl Metabolite in the Urine and Faeces of Man. J. Pharm. 1981, 33, 386-387.
42. Foster, R. T.; Carr, R. A.; Acebutolol. In Analytical Profiles of Drug Substances; Florey, K., Ed.; Academic: New York, 1990; Vol. 19, pp 1-26.
43. Artursson, P.; Karlsson, J. Correlation between Oral Drug Absorption in Humans and Apparent Drug Permeability. Biochem. Biophys. Res. Commun. 1991, 175, 880-885.
44. Harvey, S. C.; Winthrow, C. D.; Hormones. In Remington's Pharmaceutical Sciences; Gennaro, A. R. Ed.; Mack Publishing Company: Easton, PA, 1985; Vol. 17, pp 951-1001.
45. Ukabam, S. O.; Cooper, B. T. Small Intestinal Permeability to Mannitol, Lactulose, and Polyethylene Glycol 400 in Celiac Disease. Dig. Dis. Sci. 1984, 29, 809-816.
46. Cruickshank, J. M. The Clinical Important of Cardioselectivity and Lipophilicity in Beta Blockers. Am. Heart. J. 1980, 100, 160-178.
47. Ruffalo, R. L.; Garabedian-Ruffalo, S. M.; Garret, B. N. A Rational Therapeutic Approach to the Treatment of Essential Hypertension Part I. Cardiovas. Rev. Rep. 1986, 7, 692-700.
48. Meier, J. Pharmacokinetic Comparison of Pindolol with Other Beta-Adrenoceptor-Blocking Agents. Am. Heart J. 1982, 104, 364-73.
49. Ryde, E. M.; Ahnfelt, N. O. The Pharmacokinetics of Olsalazine Sodium in Healthy Volunteers After a Single I.V. Dose and After Oral Doses With and Without Food. Eur. J. Clin. Pharmacol. 1988, 34, 481-488.
50. Bodem, G.; Chidsey, C. A. Pharmacokinetic Studies of Practolol, a Beta Adrenergic Antagonist, in Man. Clin. Pharmacol. Ther. 1973, 14, 26-29.
51. Miller, R. Pharmacokinetics and Bioavailability of Ranitidine in Humans. J. Pharm. Sci. 1984, 73, 1376-1379.
52. Roila, F.; Del Favero, A. Ondansetron Clinical Pharmacokinetics. Clin. Pharmacokinet. 1995, 29, 95-109.
53. Anttila, M.; Arstila, M.; Pfeffer, M.; Tikkanen, R.; Vallinkoski, V.; Sundquist, H. Human Pharmacokinetics of Sotalol. Acta. Pharmacol. Toxicol. (Copenh) 1976, 39, 118-128.
54. Hanyok, J. J. Clinical Pharmacokinetics of Sotalol. Am. J. Cardiol. 1993, 72, 19A-26A.
55. Fowler, P. A.; Lacey, L. F.; Thomas, M.; Keene, O. N.; Tanner, R. J.; Baber, N. S. The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan. Eur. Neurol. 1991, 31, 291-294.
56. Dixon, C. M.; Saynor, D. A.; Andrew, P. D.; Oxford, J.; Bradbury, A.; Tarbit, M. H. Disposition of Sumatriptan in Laboratory Animals and Humans. Drug Metab. Dispos. 1993, 21, 761-769.
57. Shinohara, Y.; Baba, S.; Kasuya, Y. Absorption, Metabolism, and Excretion of Oral Testosterone in Humans by Mass Fragmentography. J. Clin. Endocrinol. Metab. 1980, 51, 1459-1462.
58. Acosta, E. P.; Page, L. M.; Fletcher, C. V. Clinical Pharmacokinetics of Zidovudine. Clin. Pharmacokinet. 1996, 30, 251-262.
59. Pieniaszek, H. J., Jr.; Resetarits, D. E.; Wilferth, W. W.; Blumenthal, H. P.; Bates, T. R. Relative Systemic Availability of Sulfapyridine from Commercial Enteric-Coated and Uncoated Sulfasalazine Tablets. J. Clin. Pharmacol. 1979, 1, 39-45.
60. Peterson, R. E.; Wyngaarden, J. B.; Guerra, L. S.; Brodie, B. B.; Bunim, J. J. The Physiological Disposition and Metabolic Fate of Hydrocortisone in Man. J. Clin. Invest. 1955, 34, 1778-1794.
61. Riley, S. A.; Kim, M.; Sutcliffe, F.; Rowland, M.; Turnberg, L. A. Absorption of Polar Drugs Following Caecal Instillation in Healthy Volunteers. Aliment. Pharmacol. Ther. 1992, 6, 701-706.
62. Macheras, P.; Reppas, C.; Dressman, J. B. Estimate of Volume/Flow Ratio of Gastrointestinal (GI) Fluids in Humans Using Pharmacokinetic Data. Pharm. Res. 1990, 7, 518-522.
63. Schentag, J. J.; Cerra, F. B.; Calleri, G. M.; Leising, M. E.; French, M. A.; Bernhard, H. Age, Disease, and Cimetidine in Healthy Subjects and Chronically Ill Patients. Clin. Pharmacol. Ther. 1981, 29, 737-743.
64. Amidon, G. L.; Sinko, P. J.; Fleisher, D. Estimating Human Oral Fraction Dose Absorbed: A Correlation Using Rat Intestinal Membrane Permeability for Passive and Carrier-Mediated Compounds. Pharm. Res. 1988, 5, 651-654.
65. Nicholas, P.; Meyers, B. R.; Hirschman, S. Z. Cephalexin: Pharmacologic Evaluation Following Oral and Parenteral Administration. J. Clin. Pharmacol. 1973, 13, 463-468.
66. Eichelbaum, M.; Ochs, H. R.; Roberts, G.; Somogyi, A. Pharmacokinetics and Metabolism of Antipyrine (Phenazone) after Intravenous and Oral Administration. Drug. Res. 1982, 32, 575-578.
67. Sennello, L. T.; Sonders, R. C.; Glassman, H. N.; Jordan, D. C.; Luther, R. R.; Tolman, K. G. Effect of Age on the Pharmacokinetics of Orally and Intravenously Administered Terazosin. Clin. Ther. 1988, 10, 600-607.
68. Sinko, P. J.; Leesman, G. D.; Amidon, G. L.; Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach. Pharm. Res. 1991, 8, 979-988.
69. Spyker, D. A.; Rugloski, R. J.; Vann, R. L.; O'Brien, W. M. Pharmacokinetics of Amoxicillin: Dose Dependence After Intravenous, Oral, and Intramuscular Administration. Antimicrob. Agents Chemother. 1977, 11, 132-141.
70. Blanchard, J.; Sawers, S. J. The Absolute Bioavailability of Caffeine in Man. Eur. J. Clin. Pharmacol. 1983, 24, 93-98.
71. Osman, M. A.; Patel, R. B.; Irwin, D. S.; Craig, W. A.; Welling, P. G. Bioavailability of Chlorothiazide from 50, 100, and 250 mg Solution Doses. Biopharm. Drug Dispos. 1982, 3, 89-94.
72. Shah, V. P.; Prasad, V. K.; Cabana, B. E.; Sojka, P. Thiazides II, New Pharmacokinetic Findings on Chlorothiazide Using HPLC Analysis. Curr. Ther. Res. 1981, 29, 802-814.
73. Stewart, B. H.; Kugler, A. R.; Thompson, P. R.; Bockbrader, H. N. A Saturable Transport Mechanism in the Intestinal Absorption of Gabapentin is the Underlying Cause of the Lack of Proprtionality Between Increasing Dose and Drug Levels in Plasma. Pharm. Res. 1993, 10, 276-281.
74. Chongg, S.; Dando, S. A.; Soucek, K. M.; Morrison, R. A. In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of In Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System. Pharm. Res. 1996, 13, 120-123.
75. Everette, D. W.; Olsen, S. J.; Sugarman, A. A.; Ita, C.; Stewart, M. B.; Sherman, J. W.; Kripalani, K. L. Disposition of SQ-32,756 (BV-araU) in Healthy Male Subjects. Pharm. Res. 1992, 9, S316.
76. Yu, L. X.; Crison, J. P.; Amidon, G. L. Unpublished results.
77. Tse, F. L.; Jaffe, J. M.; Troendle, A. Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers. J. Clin. Pharmacol. 1992, 32, 630-638.
78. Ranadive, S. A.; Chen, A. X.; Serajuddin, A. T. M. Relative Lipophilicities and Structural-Pharmacological Considerations of Various Angiotensin-Converting Enzyme (Ace) Inhibitors. Pharm. Res. 1992, 9, 1480-1483.
79. Lennernäs, H.; Ahrenstedt, Ö.; Ungell, A. L. Intestinal Drug Absorption During Induced Net Water Absorption in Man; A Mechanistic Study Using Antipyrine Atenolol and Enalaprilat. Br. J. Clin. Pharmacol. 1994, 37, 589-596.
80. Lennarnäs, H.; Palm, K.; Fagerholm, U.; Artursson, P. Comparison Between Active and Passive Drug Transport in Human Intestinal Epithelial(Caco-2) Cells In Vitro and Human Jejunum In Vivo. Int. J. Pharm. 1996, 127, 103-107.
81. Benet, L. Z. Pharmacokinetics/Pharmacodynamics of Furosemide in Man: A Review. J. Pharmacokinet. Biopharm. 1979, 7, 1-27.
82. Jacobson, M. A.; de Miranda, P.; Cederberg, D. M.; Burnette, T.; Cobb, E.; Brodie, H.; R.; Mills, J. Human Pharmacokinetic and Tolerance of Oral Ganciclovir. Antimicrob. Agents Chemother. 1987, 31, 1251-1254.
83. Ascalone, V.; Cisternino, M.; Sicolo, N.; De Palo, E. Bioavailability of Bromazepam in Man After Single Administration of an Oral Solution. Arzneimitttelforschung 1984, 34, 96-98.
84. Raaflaub, J.; Speiser-Courvoisier, J. Zur Pharmakokinetik Von Bromazepam Beim Menschen. Arzneimittelforschung 1974, 24, 1841-1844.
85. Kripalani, K., J.; Mckinstry, D. N.; Singhvi, S. M.; Willard, D. A.; Vukovich, R. A.; Migdalof, B. H. Disposition of Captopril in Normal Subjects. Clin. Pharmacol. Ther. 1980, 27, 636-641.
86. Hümpel, M.; Nieuweboer, B.; Milius, W.; Hanke, H.; Wendt, H.; Kinetics and Biotransformation of Lormetazepam. Clin. Pharmacol. Ther. 1980, 28, 673-679.
87. Hümpel, M.; Illi, V.; Milius, W.; Wendt, H.; Kurowski, M. The Pharmacokinetics and Biotransformation of the New Benzodiazepine Lormetazepam in Humans. Eur. J. Drug Metab. Pharmackinet. 1979, 4, 237-243.
88. Lew, K. H.; Ludwig, E. A.; Milad, M. A.; Donovan, K.; Middleton, E. Jr.; Ferry, J. J.; Jusko, W. J. Gender-Based Effects on Methylprednisolone Pharmacokinetics and Pharmacodynamics. Clin. Pharmacol. Ther. 1993, 54, 402-414.
89. Pfeffer, M.; Gaver, R. C.; Ximenez, J. Human Intravenous Pharmacokinetics and Absolute Oral Bioavailability of Cefatrizine. Antimicrob. Agents Chemother. 1983, 24, 915-920.
90. Pentikäinen, P. J.; Penttilä, A.; Neuvonen, P. J.; Gothoni, G. Rate of [14C]-Bumetanide in Man. Br. J. Clin. Pharmacol. 1977, 4, 39-44.
91. O'Callaghan, C. H.; Sykes, R. B.; Ryan, D. M.; Foord, F. D.; Muggleton, P. W. Cefuroxime-A New Cephalosporin Antibiotic. J. Antibiot. (Tokyo) 1975, 29, 29-37.
92. Hellström, K.; Rosén, A.; Swahn, A. Absorption and Decomposition of Potassium-35S-Phenoxymethyl Penicillin. Clin. Pharmacol. Ther. 1974, 16, 826.
93. Beermann, B.; Groschinsky-Grind, M. Pharmacokinetics of Hydrochlorothiazide in Man. Eur. J. Clin. Pharmacol. 1977, 12, 297-303.
94. Jamali, F.; Brocks, D. R. Clinical Pharmacokinetics of Ketoprofen and its Enantiomers. Clin. Pharmacokinet. 1990, 19, 197-217.
95. Garg, V.; Jusko, W. J. Biopharm. Bioavailability and Reversible Metabolism of Prednisone and Prednisolone in Man. Druq Dispos. 1994, 15, 163-172.
96. Thwaites, D. T.; Cavet, M.; Hirst, B. H.; Simmons, N. L. Angiotensin-Converting Enzyme (Ace) Inhibitor Transport in Human Intestinal Epithelial (Caco-2) Cells. Br. J. Pharmacol. 1995, 114, 981-986.
97. Armayor, G. M.; Lopez, L. M. Lisinopril: A New Angiotensin-Converting Enzyme Inhibitor. Drug Intell. Clin. Pharm. 1988, 22, 365-372.
98. Jung, D.; Powell, J. R.; Walson, P.; Perrier, D. Effect of Dose on Phenytoin Absorption. Clin. Pharmacol. Ther. 1980, 28, 479-485.
99. Singhvi, S. M.; Pan, H. Y.; Morrison, R. A.; Willard, D. A. Disposition of Pravastatin Sodium, A Tissue-Selective HMG-Coa Reductase Inhibitor, in Healthy Subjects. Br. J. Clin. Pharmacol. 1990, 29, 239-243.
100. Schedl, H. P. Absorption of Steroid Hormones from the Human Small Intestine. J. Clin. Endocrinol. Metab. 1965, 25, 1309-1316.
101. Hu, M.; Chen, J.; Zhu, Y.; Dantzig, A. H.; Stratford, R. E., Jr.; Kuhfeld, M. T. Mechanism and Kinetics of Transcellular Transport of a New Beta Lactam Antibiotic Loracarbef Across an Intestinal Epithelial Membrane Model System (Caco-2). Pharm. Res, 1994, 11, 1405-1413.
102. DeSante, K. A.; Zeckel, M. L. Pharmacokinetic Profile of Loracarbef. Am. J. Med. 1992, 93, 165-195.
103. Walker, M. C.; Patsalos, P. N. Clinical Pharmacokinetics of New Antiepileptic Drugs. Pharmacol. Ther. 1995, 67, 351-384.
104. Elwes, R. D.; Binnie, C. D. Clinical Pharmacokinetics of Newer Antiepileptic Drugs. Clin. Pharmacokinet. 1996, 30, 403-415.
105. Balasubramanian, R.; Klein, K. B.; Pittman, A. W.; Liao, S. H.; Findlay, J. W.; Frosolone, M. F. Pharmacokinetics of Acrivastine after Oral and Colonic Administration. J. Clin. Pharmacol. 1989, 29, 444-447.
106. Schroeder, D. H. Metabolism and Kinetics of Bupropion. J. Clin. Psychiatry 1983, 44, 79-81.
107. Goodnick, P. J. Pharmacokinetics of Second Generation Anti-depressants: Bupropion. Psychopharmacol. Bull. 1991, 27, 513-519.
108. Johansson, R.; Regårdh, C. G.; Sjögren, J. Absorption of Alprenolol in Man from Tablets with Different Rates of Release. Acta Pharm. Suec. 1971, 8, 59-70.
109. Holford, N. H. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. Clin. Pharmacokinet. 1986, 11, 483-504.
110. Edgar, B.; Regardh, C. G.; Johnsson, G.; Johansson, L.; Lundborg, P.; Löfberg, I.; Rönn, O. Felodipine Kinetics in Healthy Men. Clin. Pharmacol. Ther. 1985, 38, 205-211.
111. Edgar, B.; Regardh, C. G.; Lundborg, P.; Romare, S.; Nyberg, G.; Rönn, O. Pharmacokinetics and Pharmacodynamics Studies of Felodipine in Healthy Subjects After Various Single Oral and Intravenous Doses. Biopharm. Drug Dispos. 1987, 8, 235-248.
112. Frishman, W. H.; Tepper, D.; Lazar, E. J.; Behrman, D.; Betaxolol: A New Long-Acting Betal-Selective Adrenergic Blocker. J. Clin. Pharmacol. 1990, 30, 686-92.
113. Schwartz, D. E.; Ziegler, W. H. Assay and Pharmacokinetics of Trimethoprim in Man and Animals. Postgrad. Med. J. 1969, 45, Suppl:32-37.
114. Finn, A.; Straughn, A.; Meyer, M.; Chubb, J. Effect of Dose and Food on the Bioavailability of Cefuroxime Axetil. Biopharm. Drug Dispos. 1990, 8, 519-526.
115. Lang, C. C.; Moreland, T. A.; Davey, P. G. Bioavailability of Cefuroxime Axetil: Comparison of Standard and Abbreviated Methods. J. Antimicrob. Chemother. 1990, 25, 645-650.
116. Glazko, a. J.; Wolf, L. M.; Dill, W. A.; Bratton, C. Biochemical Studies on Chloramphenicol (Chloromectin). J. Pharmacol. Exp. Ther. 1949, 96, 445-459.
117. Glazko, A. J.; Dill, W. A.; Kazenko, A.; Wolf, L. M.; Carnes, H. E. Physical Factors Affecting the Rate of Absorption of Chloramphenicol Esters. Antibiot. Chemother. 1958, 8, 516-526.
118. Ambrose, P. J. Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate. Clin. Pharmacokinet. 1984, 9, 222-238.
119. Davies, D. S.; Wing, A. M.; Reid, J. L.; Neill, D. M.; Tippett, P.; Dollery, C. T. Pharmacokinetics and Concentration Effect Relationships of Intravenous and Oral Clonidine. Clin. Pharmacol. Ther. 1977, 21, 593-601.
120. Lowenthal, D. T.; Matzek, K. M.; MacGregor, T. R. Clinical Pharmacokinetics of Clonidine. Clin. Pharmacokinet. 1988, 14, 287-310.
121. Lowenthal, D. T. Pharmacokinetics of Clonidine. J. Cardiovasc. Pharmacol. 1980, 2, S29-S37.
122. Walker, S. R.; Richards, A. J.; Paterson, J. W. The Absorption, Excretion and Metabolism of Disodium [14C] Cromogylate in Man. Biochem. J. 1971, 125, 27P.
123. Sallee, F. R.; Pollock, B. G. Clinical Pharmacokinetics of Imipramine and Desipramine. Clin. Pharmacokinet. 1990, 18, 346-64.
124. Mandelli, M.; Tognoni, G.; Garattini, S. Clinical Pharmacokinetics of Diazepam. Clin. Pharmacokinet. 1978, 3, 72-91.
125. Jauhiainen, K.; Eksborg, S.; Kangas, L.; Perila, M.; Alfthan, O. The Absorption of Doxorubicin and Mitomycin C in Perioperative Instillation. Ear. Urol. 1985, 11, 269-272.
126. Fabris, A.; Pellanda, M. V.; Gardin, C.; Contestabile, A.; Bolzonella, R. Pharmacokinetics of Antifungal Agents. Perit. Dial. Int. 1993, 13, S280-S282.
127. Finland, M. Gentamicin: Antibacterial Activity, Clinical Pharmacology and Clinical Applications. Med. Times 1969, 97, 161-174.
128. Lee, E. J. D.; Williams, K.; Day, R.; Graham, G.; Champion, D. Stereoselective Disposition of Ibuprofen Enantiomers in Man. Br. J. Clin. Pharmacol. 1985, 19, 669-674.
129. Regazzi, B. M.; Rondanelli, R.; Ciaroelli, L.; Rampini, A. Evaluation of the Absorption from Three Ibuprofen Formulations. Int. J. Clin. Pharmacol. Res. 1986, 6, 469-473.
130. Chabner, B. A.; Donehower, R. C.; Schilsky, R. L. Clinical Pharmacology of Methotrexate. Cancer Treat. Rep. 1981, 65, 51-54.
131. Bleyer, W. A. The Clinical Pharmacology of Methotrexate. Cancer 1978, 41, 36-51.
132. Henderson, E. S.; Adamson, R. H.; Oliverio, V. T. The Metabolic Fate of Titrated Methotrexate. Cancer Res. 1965, 25, 1018-1024.
133. Delmonte, L.; Jukes, T. H. Folk Acid Antagonists in Cancer Chemotherapy. Pharmacol. Rev. 1962, 14, 91-135.
134. Freeman, M. V. The Fluorometric Measurement of the Absorption, Distribution and Excretion of Single Doses of 4-Amino-10-Methyl Pteroylglutamic Acid (Amethopterin) in Man. J. Pharmacol. Exp. Ther. 1956, 15, 154-62.
135. Stein, G. E. Review of the unavailability and Pharmacokinetics of Oral Norfloxacin. Am. J. Med. 1987, 82, 18-21.
136. Holmes, B.; Brogden, R. N.; Richards, D. M. Norfloxacin: A Review of its Antibacterial Activity, Pharmacokinetic Properties and Therapeutic Use. Drugs 1985, 30, 482-513.
137. Fourtillan, J. B.; Brisson, A. M.; Couet, W. Pharmacokinetics of Prazosin Administered as Gastro-Intestinal-Therapeutic-Systems to 24 Healthy Volunteers. Therapie 1993, 48, 115-118.
138. Guentert, T. W.; Upton, R. A.; Holford, N. H.; Bostrom, A.; Rigelman, S. Gastrointestinal Absorption of Quinidine from Some Solutions and Commercial Tablets. J. Pharmacokinet. Biopharm. 1980, 8, 243-255.
139. Beermann, B.; Hellström, K.; Rosén, A. The Gastrointestinal Absorption of Atropine in Man. Clin. Sci. 1971, 40, 95-106.
140. Golding, J. F.; Gosden, E.; Gerrell, J. Scopolamine Blood Levels Following Buccal Versus Ingested Tablets. Aviat. Space Environ. Med. 1991, 62, 521-526.
141. Gardner, M. J.; Wilner, K. D.; Hansen, R. A.; Fouda, H. G.; McMahon, G. F. Single and Multiple Dose Pharmacokinetics of Tenidap Sodium in Healthy Subjects. Br. J. Clin. Pharmacol. 1995, 39, 11S-15S.
142. Sonders, R. C. Pharmacokinetics of Terazosin. Am. J. Med. 1986, 80, 20-24.
143. Klotz, U.; Antonin, K. H. Pharmacokinetics and Bioavailability of Sodium Valproate. Clin. Pharmacol. Ther. 1976, 21, 736-743.
144. Bruni, J.; Wilder, B. J. Valproic Acid: Review of New Antiepileptic Drug. Arch. Neurol. 1979, 36, 393.
145. Gugler, R.; von Unruh, G. E. Clinical Pharmacokinetics of Valproic Acid. Clin. Pharmacokinet. 1980, 5, 67-83.
146. Clark, P. I.; Slevin, M. L. The Clinical Pharmacology of Etoposide and Teniposide. Clin. Pharmacokinet. 1987, 12, 223-252.
147. Nissen, N. I.; Hansen, H. H.; Pedersen, H.; Stroyer, I.; Dombernowsky, P.; Hessellund, M. Clinical Trial of the Oral Form of a New Podophyllotoxin Derivative, VP-16-213 (NSC-141540), in Patients with Advanced Neoplastic Disease. Cancer Chemother. Rep. 1975, 59, 1027-1029.
148. MDL Information Systems, Inc. 14600 Catalina Street, San Leandro, CA 94577.
149. Kier, L. B. Shape Indexes of Orders One and Three from Molecular Graphs. Quant. Struct.-Act. Relat. 1986, 5, 1-7.
150. Randić, M.; Brissey, G. M.; Spencer, R. B.; Wilkins, C. L. Search for all Self-Avoiding Paths for Molecular Graphs. Comput. Chem. 1979, 3, 5.
151. Wiener, H. Structural Determination of Paraffin Boiling Points. J. Am. Chem. Soc. 1947, 69, 17.
152. Kier, L. B.; Hall, L. H. Molecular Connectivity in Structure-Activity Analysis: Research Studies: Hertfordshire, England, 1986.
153. Randić, M. On Molecular Identification Numbers. J. Chem. Inf. Comput. Sci. 1984, 24, 164.
154. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P., AMI: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
155. Goldstein, H. Classical Mechanics; Addison-Wesley: Reading, MA, 1950; pp 144-156.
156. Bondi, A. van der Waals Volumes and Radii. J. Phys. Chem. 1964, 65, 441.
157. Pearlman, R. S. In Physical Chemistry Properties of Drugs; Sinkula, A. A., Valvani, S. C., Eds.; Quantum Chemistry Program Exchange No. 413. Marcel Dekker, Inc.: New York, 1980; Chapter 10.
158. Slouch, T. R.; Jurs, P. C. A Simple Method for the Representation, Quantification, and Comparison of the Volumes and Shapes of Chemical Compounds. J. Chem. Inf. Comput. Sci. 1986, 26, 4-12.
159. Stanton, D. T.; Jurs, P. C. Development and Use of Charged Partial Surface Area Structural Descriptors in Computer-Assisted Quantitative Structure-Property Relationship Studies. Anal. Chem. 1990, 62, 2323-2329.
160. Sello, G. A New Definition of Functional Groups and a General Procedure for Their Identification in Organic Structures. J. Am. Chem. Soc. 1992, 114, 3306.
161. Bohachevsky, I. O.; Johnson, M. E.; Stein, M. L. Generalized Simulated Annealing for Function Optimization. Technometrics 1986, 28, 209.
162. Sutter, J. M.; Dixon, S. L.; Jurs, P. C. Automated Descriptor Selection for Quantitative Structure-Activity Relationships Using Generalized Simulated Annealing. J. Chem. Int. Comput. Sci. 1995, 35, 77.
163. Leardi, R. Application of a Genetic Algorithm to Feature Selection Under Fall Validation Conditions and to Outlier Detection. J. Chemom. 1992, 6, 267.
164. Wessel, M. D.; Jurs, P. C. Prediction of Reduced Ion Mobility Constants from Structural Information Using Multiple Linear regression Analysis and Computational Neural Networks. Anal. Chem. 1994, 66, 2480.
165. Computer-Assisted Development of Quantitative Structure - Property Relationships and Design of Feature Selection Routines; Wessel, M. D. Ph.D. Dissertation, The Pennsylvania State University, 1997; Chapter 3.
166. Belsley, D. A.; Kuh, E.; Welsch, R. E. Regression Diagnostics; Wiley: New York, 1980.
167. Livingstone, D. J.; Manallack, D. T. Statistics Using Neural Networks: Chance Effects. J. Med. Chem. 1993, 36, 1295.
168. Sutter, J. M.; Jurs P. C. Selection of Molecular Descriptors for Quantitative Structure-Activity Relationships. In Data Handling in Science and Technology (Vol. 15) Adaption of Simulated Annealing to Chemical Optimization Problems; Kalivas, J. H., Ed.; Elsevier Science B. V.: Amsterdam, 1995; Chapler 5.
169. 158 This model employs a 6-4-1 neural network architecture. The rms error of prediction for this model is between 20 and 25%HIA units for various neural network training sessions.
170. Andrea, T. A.; Kalayeh, H. Applications of Neural Networks in Quantitative Structure-Activity Relationships of Dihydrofolate Reduclase Inhibitors. J. Med. Chem. 1991, 34, 2824-2836.
171. So, S.-S.; Richards, W. G. Application of Neural Networks: Quantitative Structure-Activity Relationships of the Derivatives of 2,4-Diamino-5-(substituted-benzyl)pyrmidines as DHFR Inhibitors. J. Med. Chem. 1992, 35, 3201-3207.
172. Suzuki, T.; Ishida, M. Application of Neural Networks in Quantitative Structure-Activity Relationships of Cytotoxicity of Antioxidants. Pharm. Sci. 1995, 1, 297-300.
173. Bishop, C. M. Neural Networks for Pattern Recognition; Oxford University Press: New York, 1995.
174. Topliss, J. G.; Edwards, R. P. Chance Factors in Studies of Quantitative Structure-Activity Relationships. J. Med. Chem. 1979, 22, 1238-1244.
175. Sutter, J. M.; Jurs, P. C. Prediction of Aqueous Solubility for a Diverse Set of Heteroatom-Containing Organic Compounds Using a Quantitative Structure-Properly Relationship. J. Chem. Inf. Comput. Sci. 1996, 36, 100-107.
176. a for Organic Oxyacids using Calculated Atomic Charges. J. Comput. Chem. 1993, 14, 1460-1467.